• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Tango Therapeutics Inc. (Amendment)

    2/14/24 4:08:57 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNGX alert in real time by email
    SC 13G/A 1 d772348dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Tango Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001

    (Title of Class of Securities)

    87583X109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint Master Fund, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN (Limited Partnership)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint Capital Advisors LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN (Limited Partnership)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint Capital Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint GP, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN (Limited Partnership)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint GP, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     John S. Clark II

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    Item 1(a).

    Name of Issuer:

    Tango Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    201 Brookline Avenue, Suite 901

    Boston, MA 02215

     

    Item 2(a).

    Names of Persons Filing:

    The name of the persons filing this report (the “Reporting Persons”) are:

     

      (i)

    Southpoint Master Fund, LP

     

      (ii)

    Southpoint Capital Advisors LP

     

      (iii)

    Southpoint Capital Advisors LLC

     

      (iv)

    Southpoint GP, LP

     

      (v)

    Southpoint GP, LLC

     

      (vi)

    John S. Clark II

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    1114 Avenue of the Americas, 22nd Floor

    New York, NY 10036

     

    Item 2(c).

    Citizenship:

     

    Southpoint Master Fund, L.P.:    Cayman Islands
    Southpoint Capital Advisors LP:    Delaware
    Southpoint Capital Advisors LLC:    Delaware
    Southpoint GP, LP:    Delaware
    Southpoint GP, LLC:    Delaware
    John S. Clark II:    United States

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    87583X109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 101,989,696 outstanding shares of Common Stock as reported in the Issuer’s Quarterly Report on Form 10-Q filed November 8, 2023.

    Shares reported herein are held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as the managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    SOUTHPOINT MASTER FUND, LP

    By: Southpoint GP, LP, its General Partner

    By: Southpoint GP, LLC, its General Partner

    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    SOUTHPOINT CAPITAL ADVISORS LP

    By: Southpoint Capital Advisors LLC, its General Partner

    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    SOUTHPOINT CAPITAL ADVISORS LLC
    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    SOUTHPOINT GP, LP

    By: Southpoint GP, LLC, its General Partner

    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    SOUTHPOINT GP, LLC
    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    JOHN S. CLARK II
    By:  

    /s/ John S. Clark II

      John S. Clark II, individually
    Get the next $TNGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNGX

    DatePrice TargetRatingAnalyst
    7/15/2026$46.00Overweight
    Analyst
    6/26/2026$60.00Hold → Buy
    Jefferies
    6/8/2026Peer Perform → Outperform
    Wolfe Research
    5/15/2026$24.00Overweight → Neutral
    Piper Sandler
    5/14/2026$27.00Buy → Hold
    Jefferies
    4/3/2026$30.00Buy
    Canaccord Genuity
    4/2/2026$30.00Buy
    Canaccord Genuity
    2/23/2026$19.00Outperform
    Mizuho
    More analyst ratings

    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tango Therapeutics Appoints Robert Azelby to Board of Directors

    BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with

    6/22/26 4:05:00 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

    BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the "Offering"). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the

    6/9/26 10:49:28 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces Proposed $500 Million Public Offering

    BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the "Offering") of $500 million of its common stock. All shares of common stock to be sold in the Offering will be offered by Tango. Tango also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stock offered in the Offering under the same terms and conditions. The Offering is subject to market conditions, and there can be no assurance as to wh

    6/8/26 4:01:00 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    SEC Filings

    View All

    SEC Form 8-K filed by Tango Therapeutics Inc.

    8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

    6/23/26 5:19:36 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Tango Therapeutics Inc.

    144 - Tango Therapeutics, Inc. (0001819133) (Subject)

    6/11/26 6:00:38 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Tango Therapeutics Inc.

    8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

    6/10/26 5:22:21 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    11/18/24 7:20:03 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

    4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 7:41:18 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 6:04:34 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Tango Therapeutics with a new price target

    Analyst initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $46.00

    7/15/26 8:51:47 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded Tango Therapeutics from Hold to Buy and set a new price target of $60.00

    6/26/26 8:42:49 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics upgraded by Wolfe Research

    Wolfe Research upgraded Tango Therapeutics from Peer Perform to Outperform

    6/8/26 11:47:16 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Financials

    Live finance-specific insights

    View All

    Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

    Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical benefit  Vopimetostat combinations with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib were generally well-tolerated Data support rapid advancement of vopimetostat plus daraxonrasib combination into Phase 3 development in first-line MTAP deleted pancreatic cancer Conference call today, June 8, 2026, at 8:00am ET BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to

    6/8/26 6:59:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

    BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast link here Barclays 28th Annual Global Healthcare Conference, Miami Hosting 1x1 meetings on Tuesday, March 10 2026 Leerink Partners Global Healthcare Conference, Miami Fireside chat

    2/18/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cance

    10/29/25 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Leadership Updates

    Live Leadership Updates

    View All

    Tango Therapeutics Appoints Robert Azelby to Board of Directors

    BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with

    6/22/26 4:05:00 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n

    3/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

    Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a

    1/8/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, R&D Crystal Adam sold $798,908 worth of shares (27,000 units at $29.59) as part of a pre-agreed trading plan and exercised 27,000 shares at a strike of $5.20 (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    7/2/26 7:23:37 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Azelby Robert was granted 5,740 shares (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    6/23/26 6:10:39 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Azelby Robert

    3 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    6/23/26 6:04:06 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tango Therapeutics Inc.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/20/24 4:24:26 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/7/24 9:35:56 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    10/28/24 9:22:40 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care